Gastroparesis Market
Number of pages: 100 | Report Format: PDF | Published date: April 13, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 8.3 billion |
|
Market Size Value in 2031 |
US$ 11.36 billion |
|
CAGR |
3.5% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Disease Type, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global gastroparesis market was valued at US$ 8.3 billion in 2022 and is expected to register a revenue CAGR of 3.5% to reach US$ 11.36 billion by 2031.
Gastroparesis Market Fundamentals
Gastroparesis (GE) is a disorder that impairs the normal spontaneous movement of the stomach muscles (motility). Strong muscle contractions normally move food through your digestive tract. However, if someone has gastroparesis, their stomach’s motility is reduced or non-existent, preventing the stomach from emptying normally. The cause of gastroparesis is unknown. It can result from diabetes, and some people get it after surgery. Certain drugs, such as opioid pain relievers, certain antidepressants, high blood pressure, and allergy treatments, can produce sluggish stomach emptying and symptoms similar to those in gastroparesis. These drugs may worsen the condition of persons who already have gastroparesis. Gastroparesis can impair digestion and produce nausea, vomiting, and abdominal discomfort. It can also have an impact on blood sugar levels and nutrition. Although there is no cure for gastroparesis, dietary adjustments and medicines can provide some comfort. A radiographic gastric emptying test is used to make the diagnosis. The two major types of gastroparesis patients are diabetics and those who develop gastroparesis for unexplained (or idiopathic) causes; nevertheless, various etiologies (uncommon and common) can result in gastroparesis syndrome. Diagnosis is made based on a radiographic gastric emptying test.
Gastroparesis, also called delayed gastric emptying, is an outdated word that does not completely represent all motor abnormalities in the gastroparesis stomach. Furthermore, there needs to be a professional consensus on the definition of gastroparesis. Some professionals reserve the term gastroparesis for severely impaired stomach emptying while using the terms delayed gastric emptying or functional dyspepsia (non-ulcer dyspepsia) for less severe signs of impaired emptying.
Identifying individuals with the relevant symptom pattern, followed by observations of delayed gastroparesis in the absence of mechanical blockage, is required to diagnose gastroparesis. Although the link between symptoms and delayed GE is debatable, most large-scale investigations have found that individuals with delayed GE for solids are more likely to experience postprandial fullness, nausea, and vomiting. Based on these findings, the European Gastroparesis Consensus defined gastroparesis as a disorder characterized by delayed GE without mechanical blockage, with nausea and vomiting as symptoms and overlapping postprandial distress syndrome. (PDS). The combination of nausea, vomiting, early satiety, and postprandial fullness, each of which are symptoms of PDS according to the Rome IV criteria, has been labeled “gastroparesis-like symptoms (GPLS).”
[56756]
Gastroparesis Market Dynamics
The rise in the prevalence of idiopathic gastroparesis will likely drive the revenue growth of the gastroparesis market during the forecast period. Furthermore, the increase in procedures that might result in post-operative gastroparesis is expected to fuel the expansion of the gastroparesis market revenue. Additionally, an increase in producer research and development for more improved drugs for treating gastroparesis is expected to expand the market. The rising prevalence of diabetes mellitus in the population will create further chances for revenue growth. On the other hand, issues associated with the negative effects of gastroparesis treatments are expected to hamper the expansion of the gastroparesis market revenue during the forecast period.
Several variables, including an increase in the diabetic population’s incidence rate, an increase in the number of surgical operations, and an increase in the geriatric population, are among the primary drivers for the gastroparesis market revenue. Gastroparesis is a condition that mostly affects type 1 and type 2 diabetics. In this condition, the stomach takes an abnormally lengthy time to discharge its contents. Medications such as erythromycin, antiemetics, and Reglan are administered to treat gastroparesis. Furthermore, due to the increasing prevalence of type 1 and type 2 diabetes, there are approx. 60 active clinical trials for gastroparesis medicines, according to data from clinicaltrials.gov in December 2022. This increases demand for these drugs and, to some extent, fuels market revenue.
Additionally, prominent manufacturers consistently invest in R&D programs to provide novel ways to existing drug therapy. For instance, Processa Pharmaceuticals, Inc., announced in October 2021 that the US FDA had cleared them to proceed with a Phase 2a clinical trial of PCS12852 in patients with moderate to severe gastroparesis, an unmet medical need condition for which patients require an alternative and safer treatment.
Some of the factors offering potential opportunities for gastroparesis market participants include the need to improve healthcare quality, an increase in the prevalence of scleroderma, which causes connective tissue damage, an increase in the prevalence of diabetes, and the development of novel diagnostic technologies. The presence of significant market players, as well as the desire for innovative medication development to treat diabetic gastroparesis, is expected to generate profitable prospects for market participants.
Furthermore, advances by leading market participants are boosting segment expansion. For instance, EVERSANA, Evoke’s commercialization partner, conducted a GIMOTI Awareness, Trial, and Usage (ATU) study in December 2021 to observe continued physician and provider awareness, trial, and utilization of GIMOTI (a drug for diabetic gastroparesis) following market developments in the second half of 2021.
The absence of scientific proof of the improvement given by prescription drugs is likely to hinder revenue growth in the global gastroparesis market. There is relatively little published clinical data for the therapy of diabetic gastroparesis. Diabetic gastroparesis is treated with drugs such as domperidone, erythromycin, and metoclopramide. However, these drugs’ approvals differ among countries, making it difficult to obtain meaningful statistics on patient improvement due to their use.
Gastroparesis Market Ecosystem
The global gastroparesis market has been analyzed from four perspectives: drug class, disease type, distribution channel, and region.
Gastroparesis Market by Drug Class
[86577]
Based on drug class, the global gastroparesis market is segmented into antiemetic agents, prokinetic agents, and botulinum toxin injections.
The prokinetic agent segment will have the largest market share during the forecast period. Prokinetic agents treat gastrointestinal symptoms such as constipation, bloating, stomach pain, and vomiting. The segment is stimulated by its availability, effectiveness, high usage, and drugs’ applicability in treating gastroparesis.
Gastroparesis Market by Disease Type
Based on disease type, the global gastroparesis market is segmented into diabetic gastroparesis, post-surgical gastroparesis, idiopathic gastroparesis, and other disease types.
The diabetic gastroparesis segment will dominate the market during the forecast period. Upper gastrointestinal symptoms are recorded in 11% to 18% of diabetic patients, according to an article published by NCBI in March 2022, with the majority of them connected with delayed stomach emptying or gastroparesis. Gastroparesis affects around 4.8% of people with type 1 diabetes, 1% of those with type 2 diabetes, and 0.1% of people who do not have diabetes. Although type 1 diabetes has a stronger relationship with gastroparesis, the frequency of gastroparesis is significantly higher in type 2 diabetes patients; hence gastroparesis linked with type 2 diabetes is seen more commonly. The increasing incidence of diabetes, increased awareness of diabetic gastroparesis, and rising product advancements by leading market participants are important drivers driving the segment’s rise.
Gastroparesis Market by Distribution Channel
Based on distribution channels, the global gastroparesis market is segmented into hospital, retail, and online pharmacy.
The hospital pharmacy segment is expected to dominate the market with the largest revenue share during the forecast. Hospital pharmacists can play a vital role in the appropriate treatment of gastroparesis by getting more involved with patient counseling on dietary advice, pharmacologic therapies, and nonpharmacologic approaches.
Gastroparesis Market by Region
Based on region, the global gastroparesis market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America is expected to dominate the market during the forecast period due to an aging population and an increase in surgical operations. North America is likely to have a significant market position in the gastroparesis market due to its huge prediabetic population, favorable reimbursement rules, and increased awareness of the illness; the United States dominated the market. For example, according to CDC data in June 2022, 96 million people aged 18 and older have prediabetes (38.0% of the adult US population). Furthermore, rising healthcare expenditures, an expanding number of hospitals, and a well-established healthcare infrastructure contribute to the region’s market domination.
Furthermore, according to IDF statistics from September 2021, an estimated 51 million persons in North America and the Caribbean area had diabetes in 2021, with that figure expected to climb to 57 million by 2030 and 63 million by 2045. Furthermore, according to Diabetes Canada statistics published in February 2022, the number of persons suffering from diabetes, including type 1, type 2 diagnosed, and type 2 undiagnosed, is expected to reach 5,719,000 in 2022, rising to 7,277,000 by 2032. It is believed that 30% of Canadians have diabetes or prediabetes, with just 10% being diagnosed with diabetes.
The Asia-Pacific gastroparesis market is expected to develop due to an increase in the usual rate of diabetes. Furthermore, the enormous untapped market potential among developing nations is expected to drive the expansion of the gastroparesis market in the region in the coming years.
Competitive Landscape of the Global Gastroparesis Market
The rising number of product releases by prominent industry players will likely boost expansion in the global gastroparesis market. EVOKE PHARMA, a specialized pharmaceutical business focused on treating gastrointestinal (GI) problems, announced the commercial introduction of Gimoti (metoclopramide) nasal spray in October 2020 to alleviate symptoms in people with acute and recurring diabetic gastroparesis. The market is concentrated due to the existence of a few numbers of global players.
The prominent market players operating in the global gastroparesis market include:
Strategic Development in the Gastroparesis Market
Gastroparesis is a disorder that impairs the normal spontaneous movement of the stomach muscles (motility). Strong muscle contractions normally move food through your digestive tract.
The expected size of the gastroparesis market in 2031 will be 11.36 billion.
The revenue CAGR of the gastroparesis market during the forecast period is expected to be 3.5%.
Some prominent market players operating in the global gastroparesis market include Abbott Laboratories, AbbVie Inc., and Cadila Pharmaceuticals.
The prokinetic agent segment led the global gastroparesis market with the largest revenue share.
*Insights on financial performance are subject to the availability of information in the public domain